AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t
Biotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Chinese pioneer Ascletis Pharma’s shares plunged nearly 45% in the first month
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl